Jiawei Li

Dr. Jiawei Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Advanced Science
Verified
Journal Article
Open access
JLJiawei Li
Jiawei Li
CNChunxue Niu
Chunxue Niu
HAHuihan Ai
Huihan Ai
XLXiaoli Li
Xiaoli Li
LZLinlin Zhang
Linlin Zhang
YBYongli Bao
Yongli Bao
The integrity of the intestinal mucosal barrier is crucial for protecting the intestinal epithelium against invasion by commensal bacteria and pathogens, thereby combating colitis. The investigation revealed that the absence of TSP50 compromised the integrity of the intestinal mucosal barrier in murine subjects. This disruption facilitated direct contact between intestinal bacteria and the intestinal epithelium, thereby increasing susceptibility to colitis. Mechanistic analysis indicated that TSP50 deficiency in intestinal stem cells (ISCs) triggered aberrant activation of the TGF‐β signaling pathway and impeded the differentiation of goblet cells in mice, leading to impairment of mucosal permeability. By inhibiting the TGF‐β pathway, the functionality of the intestinal mucosal barrier is successfully restored and mitigated colitis in TSP50‐deficient mice. In conclusion, TSP50 played a crucial role in maintaining the intestinal mucosal barrier function and exhibited the preventive effect against the development of colitis by regulating the TGF‐β signaling pathway.

3 June 2025 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
XLXiaoli Li
Xiaoli Li
RJRong Jin
Rong Jin
ZWZhaoxia Wang
Zhaoxia Wang
CNChunxue Niu
Chunxue Niu
ZSZhenbo Song
Zhenbo Song
JLJiawei Li
Jiawei Li
Inflammatory bowel disease (IBD) is a complex disease characterized by persistent chronic inflammation of the gastrointestinal tract and periodic episodes. Despite the increasing number of related studies, the detailed pathogenesis of IBD has not been elucidated. In recent years, host-microbiota interactions in the pathogenesis of IBD have received extensive attention. Testes-specific protease 50 (TSP50) is a potential risk gene for IBD, but whether it can affect the susceptibility of colitis by regulating the gut microbiome is still unclear. Here, we showed that TSP50 deficiency in neural stem cells (NSCs) aggravated colitis in mice by altering intestinal microbiome. Mechanistically, TSP50 maintained the level of neurotransmitter acetylcholine (ACh) by degrading acetylcholinesterase (AChE), thereby maintaining intestinal mucosa and intestinal microecological homeostasis and reducing the susceptibility to colitis. These findings provide a new perspective on the interaction between host and commensal microbiota, which may be beneficial for developing potential therapeutic strategies for IBD.

5 August 2025 in Aging Cell
Verified
Journal Article
Open access
XLXiaoli Li
Xiaoli Li
YCYuecong Chen
Yuecong Chen
ZGZhuoyi Gao
Zhuoyi Gao
XLXiaoling Liu
Xiaoling Liu
ZSZhenbo Song
Zhenbo Song
YBYongli Bao
Yongli Bao
Aging is a process of gradual decline in physical and cognitive function and is a major risk factor for mortality. Despite the increasing number of relevant studies, the mechanisms regulating the aging process have not been fully elucidated. Genetic factors have long been recognized as key factors in controlling the rate of aging. Testes‐specific protease 50 (TSP50) has been shown to be involved in the regulation of embryonic development and intestinal homeostasis, but its role in the regulation of aging remains unclear. Here, we showed that TSP50 expression was reduced in the hippocampus of both aged humans and mice. TSP50 deficiency in neural stem cells (NSCs) drove accelerated aging in mice, characterized by exacerbated age‐related cognitive impairments and significantly elevated neuroinflammation. Notably, aged mice with NSCs‐specific knockout of TSP50 exhibited impaired intestinal mucosal barriers, dysbiosis of gut microbiota, and a marked reduction in the production of short‐chain fatty acids (SCFAs). Restoring gut microbial ecology using fecal microbiota transplantation (FMT) and overexpressing TSP50 successfully alleviated aging‐associated cognitive decline and neuroinflammation. Taken together, our study suggests that TSP50 plays a critical role in the aging process and identifies gut microbiota as a pivotal mediator of TSP50's influence on age‐related cognitive decline and neuroinflammation. These findings highlight the potential therapeutic value of targeting TSP50 and gut microbiota for aging, offering insights into aging mechanisms and interventions for aging‐related neurodegenerative diseases.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
QSQ. Song
Q. Song
TZT. Zhang
T. Zhang
JLJiawei Li
Jiawei Li
WSWang-Huei Sheng
Wang-Huei Sheng
JWJianxun Wang
Jianxun Wang
SJS. Jiao
S. Jiao
Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is a specific immunotherapy for each individual. Our previous research has proved that the combined immunotherapy of mutant Nas-T cell and PD1 antibody is more effective than PD1 alone in prolonging PFS (World Conference on Lung Cancer 2018). We aim to evaluate the characteristics of the immune repertoire (IR) as a predictive biomarker for immunotherapy and to construct personalized and specific TCR-T. 14 patients with advanced solid tumors who failed after multiline treatments were recruited. They were divided into durable clinical benefit (complete response, partial response or stable disease for more than 3 months) and non-durable clinical benefit (DCB and NCB) based on PFS. Peripheral blood was collected at baseline and each cycle. IR-seq of the CDR3 regions of human TCRβ chains was used to interrogate the TCRs frequency. We used single neoantigen to stimulate the infused T cells and performed RNAseq for the sorted CD137(+) cells to obtain the full-length TCR α and β chain. Lastly, we constructed TCR-T cells via transfecting the TCR α/β pair into the T cells of patients and co-cultured with neoantigen to analyze the functionality of TCRs. After neoantigen pulsing, the clonality of infused T cells pool significantly increased (P = 0.0001), suggesting some tumor-specific T-cells were expanded and enriched after neoantigen pulsing. Compared to baseline, T-cell repertoire of NCB and DCB after 1st cycle displayed significant changes: Shannon 1.19 vs 0.97 (P = 0.002); clonality 0.68 vs 1.19 (P = 0.001). Elevated clonality may indicate expanded tumor-specific T-cells which could recognize mutant neoantigen specifically. Besides, based on the in vitro TCR-T experiments, the constructed TCR-T cells can specifically recognize the mutant neoantigen and lyse the target cells expressing the corresponding neoantigen. 1228P 1228P The mutant Nas-T cell is a personalized immunotherapy. IR is a potential predictive biomarker. Shunchang Jiao. Has not received any funding. All authors have declared no conflicts of interest.

25 June 2026 in MethodsX
Verified
Journal Article
Open access
JLJiawei Li
Jiawei Li
RJRong Jin
Rong Jin
XZXuanxuan Zhang
Xuanxuan Zhang
YCYuecong Chen
Yuecong Chen
HAHuihan Ai
Huihan Ai
XLXiaoli Li
Xiaoli Li
Mouse intestinal organoids are essential 3D models that retain host genetic characteristics and complex architecture, making them invaluable for intestinal biology research. However, traditional cultivation and histological processing often suffer from high operational complexity and sample loss during sectioning. This protocol provides an optimized workflow for the establishment of mouse intestinal organoid cultures and their subsequent preparation for immunohistochemistry and fluorescence staining. By refining the handling steps, the method significantly reduces total operational time while enhancing experimental quality. Furthermore, the protocol addresses common challenges in structural integrity, ensuring that the delicate crypt-villus morphology remains intact during the sectioning process. This comprehensive approach offers a robust framework for high-quality histological analysis, supported by a comparative evaluation with traditional methods to guide researchers in different experimental contexts. • Introduces a direct pellet-OCT embedding strategy that minimizes organoid transfer and sample loss during histological processing. • Enables high-quality frozen sections compatible with H&E, Alcian Blue, immunohistochemistry, and immunofluorescence staining. • Provides a practical alternative to conventional agarose-paraffin workflows while preserving organoid morphology and reducing processing complexity.

22 April 2026 in iScience
Verified
Journal Article
Open access
YCYao Chen
Yao Chen
CLChangchang Liu
Changchang Liu
RZRuonan Zhen
Ruonan Zhen
JLJiarui Li
Jiarui Li
YLYanran Li
Yanran Li
ZSZhenbo Song
Zhenbo Song
Although ceritinib, a potent ALK inhibitor, has been clinically approved for the treatment of non-small cell lung cancer, its potent cytotoxic activity against breast cancer cells and the underlying mechanisms remain largely unknown. We show that ceritinib inhibits proliferation and induces ferroptosis in breast cells. Mechanistically, ceritinib downregulates GLUT1, impairing glycolysis, inducing energy stress, and activating AMPK signaling. Activated AMPK promotes ferritinophagy, leading to iron accumulation, lipid peroxidation, and redox imbalance, ultimately triggering ferroptosis. Rescue experiments demonstrate that GLUT1 overexpression or AMPK inhibition attenuates these effects, confirming the role of the GLUT1-AMPK axis. At the molecular level, ceritinib promotes TRIM21-mediated ubiquitination and proteasomal degradation of GLUT1 through direct binding. In vivo, ceritinib suppresses tumor growth, while GLUT1 knockdown reduces its efficacy and ferroptotic response. These findings reveal a novel mechanism whereby ceritinib induces ferroptosis via GLUT1 downregulation and AMPK-dependent ferritinophagy, supporting its potential repurposing for breast cancer therapy.